Skip to main content
. 2018 Jul 21;34:35–45. doi: 10.1016/j.ebiom.2018.07.021

Table 1.

Description of the study population among colorectal cancer patients according to tumor OGN expression level.

Variables, n (%) OGN
P value
Low(n = 130) Intermediate(n = 105) High(n = 41)
Gender
 Male 81(62.3) 48(45.7) 13(31.7) 0.885
 Female 49(37.7) 57(54.3) 28(68.3)
Age, years 56.73 ± 10.887 57.86 ± 11.741 56.83 ± 9.620 0.723
T stage 0.114
 T2 18(13.8) 19(18.1) 6(14.6)
 T3 22(16.9) 17(16.2) 15(36.6)
 T4 90(69.2) 69(65.7) 20(48.8)
TNM stage 0.584
 I 10(7.7) 8(7.6) 3(7.3)
 II 42(32.3) 24(22.9) 15(36.6)
 III 52(40.0) 61(58.1) 19(46.3)
 IV 26(20.0) 12(11.4) 4(9.8)
N stage 0.8
 N0 62(47.7) 38(36.2) 20(48.8)
 N1 32(24.6) 35(33.3) 15(36.6)
 N2 36(27.7) 31(29.5) 6(14.6)
 N3 0(0) 1(1.0) 0(0)
M stage 0.1
 M0 104(80.0) 93(88.6) 37(90.2)
 M1 26(20.0) 12(11.4) 4(9.8)
Grade 0.597
 Well/ moderate 95(73.1) 77(73.3) 32(78.0)
 Poor 28(21.5) 21(20.0) 7(17.1)
Histological type 0.846
 Adenocarcinoma 122(93.8) 101(96.2) 38(92.7)
 Mucinous 8(6.2) 4(3.8) 3(7.3)
Lymph node examined 0.937
 Median 14.8 ± 6 15.1 ± 6 15 ± 5
 Tumor location 0.269
 Colon 54(1.5) 56(53.3) 19(46.3)
 Rectum 76(8.5) 49(6.7) 22(53.7)
Perineural invasion 0.31
 Negative 109(83.8) 83(79.0) 39(95.1)
 Positive 21(16.2) 22(21.0) 2(4.9)
Vascular invasion 0.235
 Negative 87(66.9) 68(64.8) 33(80.5)
 Positive 43(33.1) 37(35.2) 8(19.5)
Adjuvant Chemotherapy 0.177
 No 25(19.2) 17(16.2) 7(17.1)
 Yes 82(63.1) 79(75.2) 28(68.3)
MS /MMR status 0.697
 MSS/MMR-proficient 87(66.9) 61(58.1) 28(68.3)
 MSI/MMR-deficient 43(33.1) 44(41.9) 13(31.7)
 CEA status 0.125
 Normal 71(54.6) 70(66.7) 29(70.7)
 Elevated 53(40.8) 31(29.5) 11(26.8)

MMR indicates mismatch repair; MS, microsatellite; MSS, microsatellite stability; MSI, microsatellite instability.